Preparing for the next public debate: Universal vaccination against hepatitis B

Vaccine

Volumn 29, Issue 48, 2011, Pages 8960-8964

  Houweling, Hans ^a   Spaendonck, Marina Conyn van ^a,b   Paulussen, Theo ^a,c   Verweij, Marcel ^a,d   Ruitenberg, E Joost ^a,e  

^a Health Council of the Netherlands   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c TNO   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e ATHENA INSTITUTE   (Netherlands)

Author keywords

Communication; Controversies; Criteria; Decision making; Hepatitis B; HPV; Implementation research; Lessons; Modelling; Pandemic influenza; Universal vaccination

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; DISEASE CONTROL; EUROPE; HEALTH PROGRAM; HEPATITIS B; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; INFLUENZA A (H1N1); MASS IMMUNIZATION; NETHERLANDS; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; PUBLIC SPEAKING; VACCINATION; WESTERN EUROPE;

HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MODELS, THEORETICAL; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PUBLIC HEALTH;

EID: 82455198715     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.042     Document Type: Article

References (31)

1. World Health Organization. Hepatitis B (factsheet no. 204, revised August 2008), ; 2008 (consulted 30.08.11). http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
2. Mereckiene J., Cotter S., Lopalco P., D'Ancona F., Levy-Bruhl D., Giambi C., et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009?. Vaccine 2010, 28(28):4470-4477.
3. British Medical Association. Hepatitis B vaccination in childhood, ; 2010 (consulted 31.08.11). http://www.bma.org.uk/health_promotion_ethics/vaccination_immunisation/Hepbchildhood.jsp.
4. Houweling H., Wittevrongel C.F.W., Verweij M., Ruitenberg E.J. Public vaccination programmes against hepatitis B in the Netherlands: assessing whether a targeted or a universal approach is appropriate. Vaccine 2010, 28:7723-7730.
5. Vriend HJ, Koedijk FDH, van den Broek IVF, van Veen MG, Op de Coul ELM, van Sighem AI et al. Hepatitis B. In: National Institute for Public Health and the Environment (RIVM), editor. Sexually transmitted infections, including HIV, in the Netherlands in 2010. RIVM report 210261009/2011. Bilthoven; 2011.
6. van Houdt R., Koedijk F.D., Bruisten S.M., Coul E.L., Heijnen M.L., Waldhober Q., et al. Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: does it work?. Vaccine 2009, 27(27):3530-3535.
7. van Houdt R., Bruisten S.M., Koedijk F.D., Dukers N.H., Op de Coul E.L., Mostert M.C., et al. Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey. J Med Virol 2007, 79(7):895-901.
8. Koedijk FDH, Op de Coul ELM, Cremer J, Hahné SJM, Coutinho RA, Boot H et al. Incidentie en moleculaire epidemiologie hepatitis B virus, Nederland 2004-2007. Report nr. 210011001/2008. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu (RIVM), ; 2008 (consulted 31.08.11). http://www.rivm.nl/bibliotheek/rapporten/210011001.pdf.
9. Heijnen ML, Meerburg BG, Waldhober Q, de Vries M, Hahné SJM. Landelijke hepatitis B-vaccinatiecampagne voor gedragsgebonden risicogroepen: resultaten en veranderingen. Bilthoven: RIVM, ; 2007 (consulted 31.08.11). http://www.rivm.nl/infectieziektenbulletin/bul1811/art_hepb.html.
10. van Houdt R., Sonder G.J., Dukers N.H., Bovee L.P., van den Hoek A., Coutinho R.A., et al. Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands. Vaccine 2007, 25(14):2698-2705.
11. Kretzschmar M., Mangen M.J., van de Laar M., de Wit A. Model based analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine 2009, 27(8):1254-1260.
12. Health Council of the Netherlands. General vaccination against hepatitis B revisited. Report 2009/03E. The Hague: Health Council of the Netherlands, ; 2009 (consulted 31.08.11). http://www.gezondheidsraad.nl/en/publications/general-vaccination-against-hepatitis-b-revisited.
13. Tilson L., Thornton L., O'Flanagan D., Johnson H., Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 2008, 18(3):275-282.
14. Siddiqui M.R., Gay N., Edmunds W.J., Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine 2011, 29:466-475.
15. Mast E., Mahoney F., Kane M., Margolis H. Hepatitis B vaccine. Vaccines 2004, 299-337. Saunders, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
16. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006, 28:126-135.
17. Bonanni P., Pesavento G., Bechini A., Tiscione E., Mannelli F., Benucci C., et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003, 21(7-8):685-691.
18. Klink A. Algemene vaccinatie tegen hepatitis B in het Rijksvaccinatieprogramma (letter of the Minister of Health to the Second Chamber of parliament). The Hague: Ministry of Health, Social Wellfare and Sports (VWS), ; 2010 (consulted 31.08.11). http://www.rijksoverheid.nl/ministeries/vws/documenten-en-publicaties/kamerstukken/2010/07/22/algemene-vaccinatie-tegen-hepatitis-b-in-het-rijksvaccinatieprogramma.html.
19. Hontelez J.A., Hahné S.J., Oomen P., de Melker H. Parental attitude towards childhood HBV vaccination in The Netherlands. Vaccine 2010, 28(4):1015-1020.
20. Lippman A., Melnychuk R., Shimmin C., Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ 2007, 177(5):484-487.
21. de Kok I., Habbema J.D., Mourits M.J., Coebergh J.W., van Leeuwen F.E. Insufficient basis for the inclusion of human papillomavirus vaccination in the National Immunisation Programme in the Netherlands. Ned Tijdschr Geneeskd 2008, 152(37):2001-2004. [in Dutch].
22. van der Noordaa J., Houweling H. Grounds for the inclusion of vaccination against cervical cancer within the National Immunisation Programme. Ned Tijdschr Geneeskd 2008, 152(42):2267-2269. [in Dutch].
23. van Rijswoud E. Flu: weighing up conflicting expert information. Nature 2009, 460(7255):571.
24. Banatvala J., Van Damme P., Emiroglu N. Hepatitis B immunisation in Britain: time to change?. BMJ 2006, 332(7545):804-805.
25. Zuckerman J., van H.J., Cafferkey M., Gjorup I., Hoel T., Rummukainen M.L., et al. Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?. Lancet Infect Dis 2007, 7(6):410-419.
26. Heffernan M.E., Garland S.M., Kane M.A. Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sex Health 2010, 7(3):383-390.
27. Houweling H., Verweij M., Ruitenberg E.J. Criteria for inclusion of vaccinations in public programmes. Vaccine 2010, 28:2924-2931.
28. Chan M. WHO Director-General replies to the BMJ. BMJ 2010, 340:c3463.
29. Rondy M., van L.A., van de K.J., Rust L., de M.H. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 2010, 28(9):2070-2075.
30. van Keulen H.M., Fekkes M., Otten W., van der Pal S., Kocken P., Ruiter R., et al. 2010, TNO Quality of Life, Leiden.
31. Nys T. Paternalism in public health care. Public Health Ethics 2008, 1:64-72.